TrialPath
Recruiting

Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis

NCT06256575 · Primus Pharmaceuticals
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Treatment of Digital Ulcers in Systemic Sclerosis With Diosmin: A Randomized, Double-blind, Placebo-controlled Multi-centre Pilot Study
About this study
This study is performed to consider the safety and healing ability of diosmin in patients with systemic sclerosis (scleroderma) and open sores on their fingers (digital ulcers). The study will include 21-45 participants randomly given active product or inactive product (placebo). Two (2) out of every three (3) participants enrolled will receive active product. The participants will have four (4) visits over eight (8) weeks. At each visit physical exams and photos will be performed. Each person will also be asked a variety of questions describing level of pain and any changes to their lifestyle.
Eligibility criteria
Inclusion Criteria: * Diagnosis of systemic sclerosis (scleroderma) * At least one "active" digital ulcer * Medication for systemic sclerosis unchanged for 30 days Exclusion Criteria: * Infection or gangrene in ulcer * Citrus allergy * Unstable heart, kidney, or liver disease * Active infection of any type * Current cancer treatment or uncured cancer * Pregnancy or breast feeding
Study design
Enrollment target: 45 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2025-05-02
Estimated completion: 2027-08-15
Last updated: 2026-11-10
Interventions
Combination Product: DiosminOther: Placebo
Primary outcomes
  • • Efficacy - Number (%) of healed baseline ulcers (Screening, Day 1, Day 28, Day 56)
Sponsor
Primus Pharmaceuticals · industry
With: KGK Science Inc.
Contacts & investigators
ContactLukban · contact · jlukban@primusrx.com · (480) 483-1410
ContactMary L Sanstead · contact · msanstead@primusrx.com · 480-250-6689
InvestigatorLukban · study_director, Primus Pharmaceuticals
All locations (5)
University of CalgaryRecruiting
Calgary, Alberta, Canada
Dalhousie UniversityRecruiting
Halifax, Nova Scotia, Canada
Saint Joseph Health Care CentreRecruiting
London, Ontario, Canada
The Ottawa HospitalRecruiting
Ottawa, Ontario, Canada
Mount Sinai Health SystemRecruiting
Toronto, Ontario, Canada
Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis · TrialPath